Page last updated: 2024-11-04

3-phenylpropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-phenylpropionic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-phenylpropionic acid : A monocarboxylic acid that is propionic acid substituted at position 3 by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107
CHEMBL ID851
CHEBI ID28631
SCHEMBL ID3419
MeSH IDM0108150

Synonyms (103)

Synonym
unii-5q445in5cu
5q445in5cu ,
4-09-00-01752 (beilstein handbook reference)
3-phenyl propionic acid
beta-phenylpropionic acid
inchi=1/c9h10o2/c10-9(11)7-6-8-4-2-1-3-5-8/h1-5h,6-7h2,(h,10,11
brn 0907515
fema no. 2889
ai3-00892
ccris 3199
nsc 9272
einecs 207-924-5
phenylpropanoic acid
benzenepropionic acid
nsc9272
phenylpropionic acid
benzylacetic acid
benzenepropanoic acid
nsc-9272
.beta.-phenylpropionic acid
dihydrocinnamic acid
beta-phenylpropionate
HCI ,
beta-phenylpropioic acid
3PP ,
phenylpropanoate
hydrocinnamic acid
3-phenyl-propionic acid
C05629
3-phenylpropanoic acid
hydrocinnamate
3-phenylpropionic acid
501-52-0
3-phenylpropionic acid, 99%, fg
1AHX
1TOJ
1TOI
DB02024
1TOG
STK286011
hydrocinnamic acid, 99%
3-phenylpropionsaeure
hydrozimtsaeure
CHEBI:28631 ,
E76D1F9D-CBB1-4B91-8949-75B4F6F4C481
phenyl propionic acid
CHEMBL851 ,
BMSE000675
H0183
bdbm50304072
3-phenylpropionic acid3-phenyl-propionic acid
AKOS000119624
NCGC00256189-01
tox21_302329
dtxsid2047064 ,
dtxcid0027064
cas-501-52-0
BBL011572
FT-0616346
S6254
3-phenylpropionic acid-2,3-13c2
3-phenylpropionic acid [fhfi]
.beta.-phenylpropanoic acid
hydrocinnamic acid [mi]
BP-21020
SCHEMBL3419
3-phenylpropionicacid
3-phenyl-propanoic acid
hyrocinnamic acid
3-phenylproionic acid
3-phenyl propanoic acid
W-105981
35845-62-6
BS-3829
Z57127332
mfcd00002771
hydrocinnamic-d5 acid
F2191-0065
hydrocinnamic acid, analytical standard
hydrocinnamic acid (3-phenylpropanoic acid)
w-phenylpropanoic acid
3-phenyl-n-propionate
dihydrocinnamate
3-phenyl-n-propionic acid
b-phenylpropionate
w-phenylpropanoate
omega-phenylpropanoic acid
omega-phenylpropanoate
b-phenylpropionic acid
benzenepropionate
HY-Y1088
SY001654
A851541
CS-W019781
3pp; 3-phenylpropionic acid
Q4358522
AMY39410
3-phenylpropionic acid;3-phenylpropanoic acid;3-phenyl-n-propionic acid
3-phenylpropanoic acid;3-phenylpropionic acid
hydrocinnamic-d9 acid
i(2)-phenylpropionic acid
hydrocinnamicacid
EN300-17962

Research Excerpts

Overview

3-Phenylpropionic acid is an end-product of the bacterial degradation of unabsorbed phenylalanine in the intestinal lumen.

ExcerptReferenceRelevance
"3-Phenylpropionic acid is an end-product of the bacterial degradation of unabsorbed phenylalanine in the intestinal lumen. "( The enzymatic basis for the dehydrogenation of 3-phenylpropionic acid: in vitro reaction of 3-phenylpropionyl-CoA with various acyl-CoA dehydrogenases.
O'Shea, JJ; Rinaldo, P; Tanaka, K; Welch, RD, 1990
)
1.98

Bioavailability

ExcerptReferenceRelevance
" Isolation and identification of these metabolites may be used as references for in vivo bioavailability experiments and for investigating their bioactivity in in vitro experiments."( Development and Validation of an in vitro Experimental GastroIntestinal Dialysis Model with Colon Phase to Study the Availability and Colonic Metabolisation of Polyphenolic Compounds.
Bosscher, D; Breynaert, A; Claeys, M; Cos, P; Hermans, N; Kahnt, A; Pieters, L, 2015
)
0.42
"A novel series of 5-membered heterocycle-containing phenylpropanoic acid derivatives was discovered as potent GPR120 agonists with low clearance, high oral bioavailability and in vivo antidiabetic activity in rodents."( Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists.
Bell, A; Cai, C; Clapper, W; Gunnet, J; Haug, P; Hua, H; Jenkinson, C; Lanter, J; Leonard, J; Ma, J; Murray, WV; Nashashibi, I; Novack, A; Suckow, A; Sui, Z; Wall, M; Wang, Y; Wells, M; Winters, M; Yan, W; Zhang, X, 2017
)
0.46
" The bioavailability of HAs largely depends on the absorption and metabolism in enterohepatic circulation, in which gut microbiota plays a vital role."( Biotransformation of natural hydroxycinnamic acids by gut microbiota from normal and cerebral ischemia-reperfusion injured rats: a comparative study.
He, Y; Li, C; Shen, H; Tong, X; Wan, H; Wang, Y; Yang, J; Yu, L; Zhou, H, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Flavan-3-ol metabolic pathway070

Protein Targets (13)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)100.00000.03403.987110.0000AID450483
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Aspartate AminotransferaseEscherichia coliKd120.0000120.0000280.0000440.0000AID977611
Chain B, Aspartate AminotransferaseEscherichia coliKd120.0000120.0000280.0000440.0000AID977611
Chain A, Aspartate AminotransferaseEscherichia coliKd120.0000120.0000280.0000440.0000AID977611
Chain B, Aspartate AminotransferaseEscherichia coliKd120.0000120.0000280.0000440.0000AID977611
Chain A, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Chain B, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Chain A, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Chain A, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Chain A, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Chain B, Aspartate aminotransferaseEscherichia coliKd366.666790.00001,125.00003,400.0000AID977611
Kelch-like ECH-associated protein 1Homo sapiens (human)Kd3,200.00001.00001.76672.4000AID1776033
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
positive regulation of retinoic acid receptor signaling pathwayC-terminal-binding protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
negative regulation of cell population proliferationC-terminal-binding protein 2Homo sapiens (human)
viral genome replicationC-terminal-binding protein 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionC-terminal-binding protein 2Homo sapiens (human)
white fat cell differentiationC-terminal-binding protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIC-terminal-binding protein 2Homo sapiens (human)
in utero embryonic developmentKelch-like ECH-associated protein 1Homo sapiens (human)
ubiquitin-dependent protein catabolic processKelch-like ECH-associated protein 1Homo sapiens (human)
regulation of autophagyKelch-like ECH-associated protein 1Homo sapiens (human)
protein ubiquitinationKelch-like ECH-associated protein 1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processKelch-like ECH-associated protein 1Homo sapiens (human)
cellular response to oxidative stressKelch-like ECH-associated protein 1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityKelch-like ECH-associated protein 1Homo sapiens (human)
regulation of epidermal cell differentiationKelch-like ECH-associated protein 1Homo sapiens (human)
cellular response to interleukin-4Kelch-like ECH-associated protein 1Homo sapiens (human)
negative regulation of response to oxidative stressKelch-like ECH-associated protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
transcription corepressor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription corepressor activityC-terminal-binding protein 2Homo sapiens (human)
protein bindingC-terminal-binding protein 2Homo sapiens (human)
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptorC-terminal-binding protein 2Homo sapiens (human)
protein kinase bindingC-terminal-binding protein 2Homo sapiens (human)
protein-containing complex bindingC-terminal-binding protein 2Homo sapiens (human)
NAD bindingC-terminal-binding protein 2Homo sapiens (human)
DNA-binding transcription factor bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coregulator bindingC-terminal-binding protein 2Homo sapiens (human)
transcription coactivator activityC-terminal-binding protein 2Homo sapiens (human)
protein bindingKelch-like ECH-associated protein 1Homo sapiens (human)
identical protein bindingKelch-like ECH-associated protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingKelch-like ECH-associated protein 1Homo sapiens (human)
disordered domain specific bindingKelch-like ECH-associated protein 1Homo sapiens (human)
ubiquitin-like ligase-substrate adaptor activityKelch-like ECH-associated protein 1Homo sapiens (human)
transcription factor bindingKelch-like ECH-associated protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleusC-terminal-binding protein 2Homo sapiens (human)
synapseC-terminal-binding protein 2Homo sapiens (human)
transcription repressor complexC-terminal-binding protein 2Homo sapiens (human)
nucleusC-terminal-binding protein 2Homo sapiens (human)
nucleoplasmKelch-like ECH-associated protein 1Homo sapiens (human)
cytoplasmKelch-like ECH-associated protein 1Homo sapiens (human)
endoplasmic reticulumKelch-like ECH-associated protein 1Homo sapiens (human)
cytosolKelch-like ECH-associated protein 1Homo sapiens (human)
actin filamentKelch-like ECH-associated protein 1Homo sapiens (human)
inclusion bodyKelch-like ECH-associated protein 1Homo sapiens (human)
midbodyKelch-like ECH-associated protein 1Homo sapiens (human)
centriolar satelliteKelch-like ECH-associated protein 1Homo sapiens (human)
Cul3-RING ubiquitin ligase complexKelch-like ECH-associated protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID450474Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability at 10 uM after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID450480Inhibition of mushroom tyrosinase at 10 uM2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID450479Inhibition of mushroom tyrosinase at 3 uM2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1750491Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient at 100 uM pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis relative to control2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID450475Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability at 30 uM after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID450471Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID450468Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1392708Antioxidant activity assessed as trolox equivalents of AAPH radical scavenging activity at 10 uM preincubated for 15 mins followed by AAPH addition measured every minute for 120 mins by ORAC-FL assay
AID1149945Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID1776032Binding affinity to human recombinant His-tagged Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 1 mM by isothermal titration calorimetry2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID450472Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability at 1 uM after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1776033Binding affinity to human recombinant His-tagged Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by surface plasmon resonance method2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID450481Inhibition of mushroom tyrosinase at 30 uM2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID450476Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability at 100 uM after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID450483Inhibition of mushroom tyrosinase2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1750492Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID1296595Dissociation constant, pKa of the compound at 100 uM by capillary electrophoresis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID450466Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1392706Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 10 uM after 48 hrs by thioflavin T-based fluorometric assay relative to control
AID1776034Binding affinity to human recombinant His-tagged Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) at 1 mM by saturation transfer difference-NMR analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID450478Inhibition of mushroom tyrosinase at 1 uM2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1392707Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation after 48 hrs by thioflavin T-based fluorometric assay
AID450482Inhibition of mushroom tyrosinase at 100 uM2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1296594Apparent permeability of compound at pH 7.4 at 200 uM by PAMPA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID450470Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 100 uM after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1296596Percentage unbound in human plasma at 5 uM after 6 hrs by equilibrium dialysis method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID450469Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1298930Inhibition of recombinant His6-tagged CtBP2 (31 to 384 residues) (unknown origin) dehydrogenase activity expressed in Escherichia coli BL21-Codonplus (DE3)-RIL cells using MTOB as substrate after 15 mins by NADH consumption assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).
AID450477Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID12965911-octonol-aqueous buffer distribution coefficient, log D of the compound at pH 7.4 incubated for 1 hr by LC-MS/MS based shake flask method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID1296593Effective permeability of compound assessed as membrane retention at pH 7.4 at 200 uM after 5 hrs by PAMPA relative to control2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID1296590Kinetic solubility in aqueous phosphate buffer at pH 7.4 at 200 uM after 24 hrs by HPLC-MS analysis2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID450473Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability at 3 uM after 68 hrs by WST8 assay2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID1296592Effective permeability of compound at pH 7.4 at 200 uM after 5 hrs by PAMPA2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Structure Property Relationships of Carboxylic Acid Isosteres.
AID450467Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs2009Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16
Melanogenesis inhibitors from the rhizomes of Alpinia officinarum in B16 melanoma cells.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1995Nature structural biology, Jul, Volume: 2, Issue:7
Alternating arginine-modulated substrate specificity in an engineered tyrosine aminotransferase.
AID1811Experimentally measured binding affinity data derived from PDB1995Nature structural biology, Jul, Volume: 2, Issue:7
Alternating arginine-modulated substrate specificity in an engineered tyrosine aminotransferase.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Biochemistry, Oct-12, Volume: 43, Issue:40
Narrowing substrate specificity in a directly evolved enzyme: the A293D mutant of aspartate aminotransferase.
AID1811Experimentally measured binding affinity data derived from PDB2004Biochemistry, Oct-12, Volume: 43, Issue:40
Narrowing substrate specificity in a directly evolved enzyme: the A293D mutant of aspartate aminotransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (128)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (11.72)18.7374
1990's28 (21.88)18.2507
2000's30 (23.44)29.6817
2010's40 (31.25)24.3611
2020's15 (11.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.89 (24.57)
Research Supply Index4.90 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index81.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.75%)6.00%
Case Studies1 (0.75%)4.05%
Observational1 (0.75%)0.25%
Other130 (97.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]